Type of information: IPO
Company: Mereo BioPharma (UK)
Funding type: IPO
- • On December 18, 2017, Mereo BioPharma announced that it plans to conduct a registered initial public offering in the United States. The number of shares and price of the proposed offering have not yet been determined. The proposed offering is expected to commence in the first half of 2018, after the U.S. Securities and Exchange Commission completes its review process of the registration statement relating to the proposed offering and subject to market and other conditions.
Therapeutic area: Rare diseases - Genetic diseases